Heron Therapeutics
(HRTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2004 | 03-2004 | 12-2003 | 09-2003 | 06-2003 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 5,813 | 2,400 | 97 | 1,473 | 1,245 |
| Marketable Securities | 10,844 | 5,344 | 9,387 | 9,620 | 10,830 |
| Receivables | 1,287 | 1,466 | 1,340 | 1,267 | 1,341 |
| TOTAL | $18,406 | $9,631 | $11,258 | $12,753 | $13,927 |
| Non-Current Assets | |||||
| PPE Net | 1,366 | 1,349 | 1,430 | 1,454 | 1,505 |
| Other Non-Current Assets | 282 | 287 | 467 | 472 | 477 |
| TOTAL | $1,648 | $1,636 | $1,897 | $1,926 | $1,982 |
| Total Assets | $20,054 | $11,267 | $13,155 | $14,679 | $15,909 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 374 | 1,201 | 476 | 295 | 377 |
| Accrued Expenses | 1,283 | 1,128 | 1,226 | 1,405 | 1,305 |
| TOTAL | $1,833 | $2,519 | $1,892 | $2,027 | $2,156 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 176 | 190 | 190 | 327 | 474 |
| TOTAL | $N/A | $N/A | $N/A | $75 | $145 |
| Total Liabilities | $1,833 | $2,519 | $1,892 | $2,102 | $2,301 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 312 | 259 | 258 | 258 | 257 |
| Common Shares | 98,865 | 86,936 | 206 | 86,762 | 86,716 |
| Retained earnings | -80,642 | -78,197 | -75,598 | -74,220 | -73,162 |
| Other shareholders' equity | -2 | 9 | 17 | 35 | 54 |
| TOTAL | $18,221 | $8,748 | $11,263 | $12,577 | $13,608 |
| Total Liabilities And Equity | $20,054 | $11,267 | $13,155 | $14,679 | $15,909 |